NEW YORK, Jan. 29 Reportlinker.com announces that a new market research report is available in its catalogue:
Osteoporosis Therapeutics - A Global Market Perspective
Advertisement
http://www.reportlinker.com/p0164234/Osteoporosis-Therapeutics---A-Global-Market-Perspective.html
Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.
Advertisement
These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
OSTEOPOROSIS THERAPEUTICS BMR-1034
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. OUTLOOK 4
3. INDUSTRY OVERVIEW 4
Osteoporosis Therapeutics: An Evolutionary Scan 4
"A Sketch of the Present Industry Scenario" 5
Facts & Figures: The Osteoporosis Primacy 5
Snapshots 5
Factors Influencing Demand 6
Competitive Landscape 6
Market Trends and Issues 8
Can New Treatments Beat the Gold Standard? 8
Oral Calcitonin Likely to Emerge as Wonder Drug 9
New Bisphosphonates Challenge Established Brands 10
Side Effects of HRT Fuel Natural Alternatives Sales 10
Bone Formation Drugs Augur New Prospects 10
Estrogen Replacement Therapy: Will Dosing Make a Difference? 12
Is Prevention Always Better Than Cure? 12
Peptide-Based Osteoporosis Therapy Gaining Ground 12
Polymorphism- A Potent Diagnostic Marker 12
Bisphosphonates - The Other Side 13
Efficacy of Evista Under the Scanner 14
4. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE 14
ERT Drugs 14
Ups and Downs in the ERT Market 14
Bisphosphonates 15
The leading Therapeutic Market 15
SERMs (Selective Estrogen Receptor Modulators) 15
Market Overview 15
Calcitonins 15
Market Overview 15
5. PRODUCT FACTS 16
Bisphosphonates 16
Hormone Replacement Therapy/ Estrogen Replacement Therapy 16
Estrogens 16
Estrogens/Progesterones 16
Calcitonins 17
Selective Estrogen Receptor Modulators (SERMs) 17
Other Therapeutics 17
6. MAJOR CLINICAL TRIALS/FINDINGS 17
7. CORPORATE DEVELOPMENTS 18
Schering-Plough Acquires Organon BioSciences 18
Faes Farma Signs Marketing Agreement with Roche and
GlaxoSmithKline 19
Alethia and Emerillon Collaborate on Osteoporosis Therapies 19
Ipsen Enters into Co-marketing Agreement with MSD 19
Unigene Enters into Agreement with Novartis 20
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs 20
Procter & Gamble Terminates Nasal Spray Collaboration with
Nastech- Pharmaceutical 20
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics 21
Radius Initiates Phase II Trials for BA058 21
Novartis and Nordic Initiate Phase III Clinical Trial of Oral
Salmon Calcitonin 21
Medivir Initiates First Human Trials for MIV-701 22
P&G Receives FDA Approval for New Dosage of Actonel 22
Takeda Introduces Benet® for Osteoporosis Treatment 22
Labtec Obtains Approval to Market Hormone Replacement Patch
in Europe 23
Wyeth Obtains Conditional Approval for Osteoporosis Drug from
FDA 23
Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval 23
Japanese Pharma Majors Receive Approval for Generic
Osteoporosis Drug 24
8. MAJOR PLAYERS 24
Eli Lilly and Company (US) 24
F.Hoffmann-La Roche Ltd (Switzerland) 25
Merck & Co., Inc. (US) 25
Novartis AG (Switzerland) 25
Novo Nordisk A/S (Denmark) 25
Organon 25
Procter & Gamble Pharmaceuticals Inc. (US) 26
Sanofi-Aventis SA (France) 26
Servier SA (France) 26
Solvay Pharmaceuticals Inc. (US) 26
Unigene Laboratories, Inc. (US) 26
Wyeth (US) 27
9. GLOBAL MARKET ANALYTICS 27
10. THE UNITED STATES 32
Industry Overview 32
Osteoporosis in the US: An Insight 32
Osteoporosis - An Underserved Market? 32
Osteoporosis Prescription Market 33
Competitive Scenario 34
Competitive Review by Segment 34
Bisphosphonates 34
SERMs 35
Calcitonins 36
PTH Therapy 36
11. JAPAN 37
12. EUROPE 38
a. France 42
b. Germany 43
c. The United Kingdom 44
d. Italy 45
e. Spain 46
f. Rest of Europe 47
13. REST OF WORLD 48
Prevalence of Osteoporosis in Various Region-At a Glance 48
Korea 48
China 48
EXHIBITS
Table 1: Prevalence of Osteoporosis and Osteopenia in Major
Markets Worldwide - 2008 & 2013
Table 2: Percentage Breakdown of Leading Players in the Global
Osteoporosis Market - 2006
Table 3: Leading Osteoporosis Drugs Worldwide by Dollar Sales -
2006
Table 4: Leading Osteoporosis Therapies and its Cost per Day
Table 5: Global Osteoporosis Therapeutics Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Osteoporosis
Therapeutics Market by Region for the Years 2008 & 2012
Table 7: Global Bisphosphonates Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Bisphosphonates Market
by Region for the Years 2008 & 2012
Table 9: Global ERT Drugs Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global ERT Drugs Market by
Region for the Years 2008 & 2012
Table 11: Global SERM Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global SERM Market by Region
for the Years 2008 & 2012
Table 13: Global Calcitonins Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Global Calcitonins Market by
Region for the Years 2008 & 2012
Table 15: Market Shares of Leading Osteoporosis Drugs in the
US -2006
Table 16: Market Shares of Leading Players in the US
Osteoporosis Market - 2004
Table 17: Market Shares of Leading Players in the US
Bisphosphonates Market - 2004
Table 18: Osteoporosis Therapeutics Market by Product Group in
the US: 2007-2015 (Sales in US$ Million)
Table 19: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in the US for the Years 2008 & 2012
Table 20: Osteoporosis Therapeutics Market by Product Group in
Japan: 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Japan for the Years 2008 & 2012
Table 22: Market Shares of Leading Players in the European
Market for Osteoporosis Therapeutics (2005)
Table 23: Osteoporosis Therapeutics Market by Region in
Europe: 2007-2015 (Sales in US$ Million)
Table 24: Percentage Breakdown of Osteoporosis Therapeutics
Market by Region in Europe for the Years 2008 & 2012
Table 25: Osteoporosis Therapeutics Market by Product Group in
Europe: 2007-2015 (Sales in US$ Million)
Table 26: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Europe for the Years 2008 & 2012
Table 27: Osteoporosis Therapeutics Market by Product Group in
France: 2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in France for the Years 2008 & 2012
Table 29: Osteoporosis Therapeutics Market by Product Group in
Germany: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Germany for the Years 2008 & 2012
Table 31: Osteoporosis Therapeutics Market by Product Group in
The UK: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in The UK for the Years 2008 & 2012
Table 33: Osteoporosis Therapeutics Market by Product Group in
Italy: 2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Italy for the Years 2008 & 2012
Table 35: Osteoporosis Therapeutics Market by Product Group in
Spain: 2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Spain for the Years 2008 & 2012
Table 37: Osteoporosis Therapeutics Market by Product Group in
Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Rest of Europe for the Years 2008
& 2012
Table 39: Percentage Breakdown of Leading Brands in the Korean
Osteoporosis Therapeutics Market - 2005
Table 40: Osteoporosis Therapeutics Market by Product Group in
Rest of World: 2007-2015 (Sales in US$ Million)
Table 41: Percentage Breakdown of Osteoporosis Therapeutics
Market by Product Group in Rest of World for the Years 2008
& 2012
COMPANIES PROFILED
To order this report:
Therapy Industry: Osteoporosis Therapeutics - A Global Market Perspective
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
